Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25372646 | 0.91 | PTPN1 (0.49) | ABCB1ALOX5SMN1; SMN2PTPN1STING1 | |
| SCHEMBL25371537 | 0.83 | AKR1C4 (0.56) | ABCB1CYP4F2CYP4A11SMN1; SMN2PTPN1 | |
| SCHEMBL25372357 | 0.83 | ABCB1 (0.46) | ABCB1ALOX5TDP1CYP4F2CYP4A11 | |
| SCHEMBL25373139 | 0.81 | APP (0.52) | ABCB1ALOX5TDP1CYP4F2CYP4A11 | |
| SCHEMBL25374554 | 0.81 | PTPN1 (0.41) | ABCB1CYP4F2CYP4A11SMN1; SMN2PTPN1 | |
| SCHEMBL25373898 | 0.81 | STING1 (0.41) | ABCB1SMN1; SMN2TSHRSTING1 | |
| SCHEMBL25370456 | 0.80 | PTPN1 (0.39) | ABCB1ALOX5TDP1CYP4F2CYP4A11 | |
| SCHEMBL25373004 | 0.80 | ALOX5 (0.41) | ABCB1ALOX5TDP1CYP4F2CYP4A11 | |
| SCHEMBL6293628 | 0.78 | THRA (0.55) | SMN1; SMN2PTPN1THRATHRB | |
| SCHEMBL16049214 | 0.76 | CYP4F2 (0.54) | ALOX5TDP1CYP4F2CYP4A11THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | ABCB1 4159/4885ALOX5 1229/4885TDP1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.